Skip to content
Search

Latest Stories

Top Stories

How the government can solve America's obesity epidemic

How the government can solve America's obesity epidemic
Getty Images

Pearl is a clinical professor of plastic surgery at the Stanford University School of Medicine and is on the faculty of the Stanford Graduate School of Business. He is a former CEO of The Permanente Medical Group.

Dying younger. Living harder. Going broke. It is difficult to overstate the longitudinal effects of excess weight in America.


An estimated seven in ten Americans are overweight or obese. The combination, according to the National Institutes of Health, results in an estimated 300,000 preventable deaths per year with extreme obesity lowering life expectancy by 14 years on average.

Added weight not only makes everyday life more difficult, but it also produces serious health consequences that include cardiovascular disease, diabetes, musculoskeletal disorders and cancer. In total, obesity costs an estimated $260 billion annually in inpatient and outpatient care.

Whether weight gain is caused primarily by genetics, societal influences or individual will, scientists aren’t altogether sure. What’s clear, however, is that most efforts to lose weight ultimately fail.

New Hope In Diabetes Drugs

Ozempic, one of a new class of medications, has been shown in studies to spur significant weight loss. The others include Mounjaro, Rybelsus and Wegovy with several new (and convenient, pill-based) options in development.

Sign up for The Fulcrum newsletter

A Heavy Price For Weight Loss

Last year, more than five million Americans were prescribed one of these drugs for weight reduction.

The annual price of treatment ranges from $12,000 (Mounjaro) to upwards of $16,000 per year (Wegovy). As a result, most users are either wealthy or have generous health-insurance coverage.

But as more Americans seek these medications for moderate weight loss, not diabetes, insurers have started clamping down. They’ve issued threatening letters to doctors, warning they’ll be referred to state regulatory boards for writing “off-label” prescriptions.

The Ozempic Paradox: Highly Effective But Unaffordable

Ozempic and other medications that help with weight loss are part of an ongoing national debate in which two competing truths collide.

The first truth is that these drugs work, leading to significant and sustained weight reduction: 14 to 25 pounds per individual on average during the medication course. And while they’re not a replacement for proper nutrition, exercise or healthier living, they do reduce the likelihood of heart attack, stroke and cancer.

Second, despite the medical opportunity at hand, making these drugs available to all 100 million obese American adults would prove cost prohibitive for businesses, private insurers and the government.

This means that the medications could drastically rollback the nation’s $260 billion in obesity-related medical expenses each year, but prescribing them at today’s prices would cost more than $1.5 trillion annually—increasing national healthcare expenditures by as much as 25 percent.

What’s more, these medications are considered “forever drugs,” requiring users to either maintain their dosage or regain most of the weight they lost.

Insurers are eager to draw a line between those seeking prescriptions for appearance’s sake and those at heightened risk of disease or death. They’re happy to cover the latter but, as with cosmetic surgery, insurers believe patients should foot the bill for the former.

Lost in this debate is an important question: Why not figure out how to make these lifesaving drugs broadly available and affordable?

The U.S. Government Can Lead The Way

With hundreds of thousands of obesity-related deaths each year, the magnitude of the problem qualifies as an “epidemic” and justifies forceful government intervention.

The current administration, with congressional approval, could initiate a nationwide campaign to fight obesity, similar to Operation Warp Speed. The program, with a $10 billion upfront investment, led to the speedy development of a safe and effective coronavirus vaccine. The government then was able to purchase more than one billion doses at one-third the cost of the vaccine’s current list price.

Here’s how the administration could replicate Operation Warp Speed to fight the obesity epidemic without breaking the bank.

Operation: Slim Provisions

The government would invest $4 billion up front— twice the average R&D cost to bring a new drug to market.

In return for funding and a ten year contract, the first drugmaker to develop a safe and effective weight-loss drug would be required to sell that medication back to the government at $40 per dose (or $2,000 per patient/year), significantly below the retail price of Ozempic and similar drugs. The winning pharma company would benefit financially, earning up to $1.2 trillion in sales over the contract’s lifetime without having to shoulder R&D costs.

With the new medication in hand, government-sponsored health programs, Medicaid and Medicare, would make it available to all obese enrollees (roughly 60 million people) for the next decade.

And by providing the drug to more than half of all obese adults, the government would reduce medical expenses by up to $130 billion annually or $1.3 trillion over 10 years, making the effort cost-neutral for American taxpayers.

Risks vs. Rewards

The only financial risk to the government (outside of defending likely lawsuits) would be failing in its search for a new drug, thus wasting the

$4 billion of taxpayer money. But that’s a relatively insignificant sum compared to the potential healthcare benefits.

The role of government is to protect the health and financial well-being of the nation. Fulfilling that function led to a lifesaving Covid-19 vaccine. Doing so again is the best option our nation has to address America’s growing obesity epidemic.

Read More

Carolyn Lukensmeyer Turns 80: A Life of Commitment to “Of, By, and for the People”

Carolyn Lukensmeyer.

The National Institute for Civil Discourse and New Voice Strategies

Carolyn Lukensmeyer Turns 80: A Life of Commitment to “Of, By, and for the People”

I’ve known Dr. Carolyn Lukensmeyer for over a decade, first meeting her about a decade ago. Dr. Lukensmeyer is a nationally renowned expert in deliberative democracy, a former executive director emerita of the National Institute for Civil Discourse, and a member of the American Academy of Arts & Sciences’ Commission on the Practice of Democratic Citizenship.

On the weekend of her 80th birthday, former colleagues, clients, and friends offered a look at Dr. Lukensmeyer’s extraordinary commitment to “of, by, and for the peoples,” from her earlier days in Iowa and Ohio to the present day.

Keep ReadingShow less
Public Health: Ban First, Study Later? The Growing Assault on Fluoridated Water

Someone getting tap water.

Getty Images, urbazon

Public Health: Ban First, Study Later? The Growing Assault on Fluoridated Water

On May 15, Florida became the second state in the nation to ban fluoride from public drinking water. The bill, signed by Governor Ron DeSantis, is set to go into effect on July 1. Utah’s Governor Spencer Cox enacted a similar ban that went into effect this May. Five other states—Kentucky, Louisiana, Massachusetts, Nebraska, and South Carolina—have introduced bills that aim to ban fluoride in public drinking water.

Fluoride is a mineral that, in small quantities, has proven to be effective against tooth decay, caused by bacteria that form in the mouth when we eat or drink. The American Academy of Pediatrics states on its website that studies have shown water fluoridation, an intentional treatment process of public drinking water, reduces tooth decay by about 25% in children and adults alike.

Keep ReadingShow less
POLL: Americans Wary About The President Taking Unconventional Actions
APM Research Lab

POLL: Americans Wary About The President Taking Unconventional Actions

Americans show a strong preference for their elected executives — governors as well as the president — to achieve their political goals through conventional, sometimes slow, procedures, according to the McCourtney Institute for Democracy’s latest Mood of the Nation Poll.

Results showed marked partisan differences. For example, 26% of all survey respondents rated a presidential action of firing all recently hired federal employees as “very appropriate,” including only four percent of Democrats and just over half of Republicans.

Keep ReadingShow less
The U.S. Is Rushing To Make AI Deals With Gulf Countries, But Who Will Help Keep Children Safe?

A child's hand holding an adult's hand.

Getty Images, LaylaBird

The U.S. Is Rushing To Make AI Deals With Gulf Countries, But Who Will Help Keep Children Safe?

As the United States deepens its investments in artificial intelligence (AI) partnerships abroad, it is moving fast — signing deals, building labs, and exporting tools. Recently, President Donald Trump announced sweeping AI collaborations with Gulf countries like Saudi Arabia and the United Arab Emirates. These agreements, worth billions, are being hailed as historic moments for digital diplomacy and technological leadership.

But amid the headlines and handshakes, I keep asking the same question: where is child protection in all of this?

Keep ReadingShow less